An autoantibody against melanoma differentiation–associated gene-5 (MDA5) can be used to distinguish a unique subgroup of patients with polymyositis/dermatomyositis who exhibit clinically amyopathic dermatomyositis, particularly when complicated by acute progressive interstitial lung disease14. This evidence concerns the gene IFIH1 and dermatomyositis.